Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer

被引:8
|
作者
Wang, Yunzhen [1 ]
Huang, Sha [1 ]
Feng, Xiangwei [1 ]
Xu, Wangjue [2 ]
Luo, Raojun [1 ]
Zhu, Ziyi [1 ]
Zeng, Qingxin [1 ]
He, Zhengfu [1 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Thorac Surg, Sch Med, Hangzhou, Peoples R China
[2] Longyou Cty Peoples Hosp, Dept Thorac Surg, Longyou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; neoadjuvant immunotherapy; chemo-immunotherapy; efficacy prediction; biomarkers; IMMUNE CHECKPOINT INHIBITORS; PLATINUM-BASED CHEMOTHERAPY; TUMOR MUTATIONAL BURDEN; LYMPHOCYTE RATIO NLR; PD-L1; EXPRESSION; NSCLC-PATIENTS; FREE SURVIVAL; PEMBROLIZUMAB; OUTCOMES; MULTICENTER;
D O I
10.3389/fonc.2023.1145128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight cancer is fast developing. Neoadjuvant treatment in NSCLC is undergoing unprecedented change. Chemo-immunotherapy combinations not only seem to achieve population-wide treating coverage irrespective of PD-L1 expression but also enable achieving a pathological complete response (pCR). Despite these recent advancements in neoadjuvant chemo-immunotherapy, not all patients respond favorably to treatment with ICIs plus chemo and may even suffer from severe immune-related adverse effects (irAEs). Similar to selection for target therapy, identifying patients most likely to benefit from chemo-immunotherapy may be valuable. Recently, several prognostic and predictive factors associated with the efficacy of neoadjuvant immunotherapy in NSCLC, such as tumor-intrinsic biomarkers, tumor microenvironment biomarkers, liquid biopsies, microbiota, metabolic profiles, and clinical characteristics, have been described. However, a specific and sensitive biomarker remains to be identified. Recently, the construction of prediction models for ICI therapy using novel tools, such as multi-omics factors, proteomic tests, host immune classifiers, and machine learning algorithms, has gained attention. In this review, we provide a comprehensive overview of the different positive prognostic and predictive factors in treating preoperative patients with ICIs, highlight the recent advances made in the efficacy prediction of neoadjuvant immunotherapy, and provide an outlook for joint predictors.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
    Hanfei Guo
    Wenqian Li
    Lei Qian
    Jiuwei Cui
    Chinese Journal of Cancer Research, 2021, 33 (02) : 203 - 215
  • [22] The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Jiang, L.
    Luo, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S1226 - S1226
  • [23] The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Long Jiang
    Jia Huang
    Shanshan Jiang
    Wenwen Rong
    Yaofeng Shen
    Chongwu Li
    Yu Tian
    Junwei Ning
    Xiaoke Chen
    Yunhai Yang
    Zhengping Ding
    Ziming Li
    Qingquan Luo
    Cancer Immunology, Immunotherapy, 2021, 70 : 2313 - 2321
  • [24] The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Jiang, Long
    Huang, Jia
    Jiang, Shanshan
    Rong, Wenwen
    Shen, Yaofeng
    Li, Chongwu
    Tian, Yu
    Ning, Junwei
    Chen, Xiaoke
    Yang, Yunhai
    Ding, Zhengping
    Li, Ziming
    Luo, Qingquan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2313 - 2321
  • [25] Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
    Parekh, Jay
    Parikh, Kaushal
    Reuss, Joshua E.
    Friedlaender, Alex
    Addeo, Alfredo
    CURRENT ONCOLOGY REPORTS, 2023, 25 (08) : 913 - 922
  • [26] The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Jiang, L.
    Huang, J.
    Luo, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S1383 - S1383
  • [27] Systematic Review of Neoadjuvant Immunotherapy for Patients With Non-Small Cell Lung Cancer
    Cao, Christopher
    Guo, Allen
    Chen, Christopher
    Chakos, Adam
    Bott, Matthew
    Yang, Chi-Fu Jeffrey
    Zielinski, Rob
    Melfi, Franca
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2021, 33 (03) : 850 - 857
  • [28] Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
    Jay Parekh
    Kaushal Parikh
    Joshua E. Reuss
    Alex Friedlaender
    Alfredo Addeo
    Current Oncology Reports, 2023, 25 : 913 - 922
  • [29] Systematic review of neoadjuvant immunotherapy for patients with non-small cell lung cancer
    Le, Anthony
    Guo, Allen
    Chen, Christopher
    Chakos, Adam
    Bott, Matthew
    Yang Chi-Fu
    Zielinski, Rob
    Melfi, Franca
    Cao, Christopher
    LUNG CANCER, 2021, 156 : S32 - S32
  • [30] Efficacy of intestinal microorganisms on immunotherapy of non-small cell lung cancer
    Xu, Hua
    Deng, Yongchun
    Zhu, Qing
    Li, Feng
    Liu, Na
    Cheng, Jun
    Qiu, Min
    HELIYON, 2024, 10 (09)